These results imply that sunitinib‐induced KDR inhibition significantly suppresses growth signaling and induces cell cycle arrest, mainly through the P53‐independent pathway, eventually causing cell death in advanced thyroid cancers. Here, TP53 is linked to thyroid gland carcinoma.